Author: Brenda Marie Rivers|| Date Published: March 3, 2021
The Biden administration is supporting collaboration between Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK) to produce more COVID-19 vaccine doses through the Defense Production Act.
At the White House’s request, the Department of Health and Human Services has earmarked $105 million in initial funds to help Merck (NYSE: MRK) expand company facilities in order to manufacture vaccine J&J developed to treat the novel coronavirus, HHS said Tuesday.
The DPA investment covers the production of vaccine substance and fill-finish vial procedures under the management of J&J’s Janssen Pharmaceuticals business.
HHS noted the large-scale vaccine manufacturing effort seeks to address the U.S. government’s goal of having 100 million vaccine doses available by the end of June.
Merck will update facilities to support vaccine validation and qualification activities with funds to be executed through the HHS’ Biomedical Advanced Research and Development Authority.
The White House also asked the Department of Defense to support J&J in daily logistics operations.
Amentum Mitie Pacific has secured an indefinite-delivery/indefinite-quantity contract with a potential value of $656.4 million to provide base operating support…
CACI International has secured a potential five-year, $416 million SeaPort-Next Generation task order to sustain and modernize information technology systems…
Cherry Bekaert has acquired accounting and advisory firm Tarsus to expand outsourced accounting, real-time financial reporting and strategic chief financial…
General Dynamics Information Technology has received a U.S. Navy contract worth $988 million to modernize and integrate command, control, communications,…
